ASMB
Price
$17.31
Change
+$0.23 (+1.35%)
Updated
Jun 27 closing price
Capitalization
132.21M
RGNX
Price
$8.39
Change
-$0.36 (-4.11%)
Updated
Jun 27 closing price
Capitalization
422.76M
31 days until earnings call
Interact to see
Advertisement

ASMB vs RGNX

Header iconASMB vs RGNX Comparison
Open Charts ASMB vs RGNXBanner chart's image
Assembly Biosciences
Price$17.31
Change+$0.23 (+1.35%)
Volume$31.33K
Capitalization132.21M
REGENXBIO
Price$8.39
Change-$0.36 (-4.11%)
Volume$1.19M
Capitalization422.76M
ASMB vs RGNX Comparison Chart in %
Loading...
ASMB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ASMB vs. RGNX commentary
Jun 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ASMB is a Hold and RGNX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 29, 2025
Stock price -- (ASMB: $17.31 vs. RGNX: $8.39)
Brand notoriety: ASMB and RGNX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ASMB: 129% vs. RGNX: 105%
Market capitalization -- ASMB: $132.21M vs. RGNX: $422.76M
ASMB [@Biotechnology] is valued at $132.21M. RGNX’s [@Biotechnology] market capitalization is $422.76M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ASMB’s FA Score shows that 0 FA rating(s) are green whileRGNX’s FA Score has 1 green FA rating(s).

  • ASMB’s FA Score: 0 green, 5 red.
  • RGNX’s FA Score: 1 green, 4 red.
According to our system of comparison, ASMB is a better buy in the long-term than RGNX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ASMB’s TA Score shows that 3 TA indicator(s) are bullish while RGNX’s TA Score has 4 bullish TA indicator(s).

  • ASMB’s TA Score: 3 bullish, 4 bearish.
  • RGNX’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, ASMB is a better buy in the short-term than RGNX.

Price Growth

ASMB (@Biotechnology) experienced а -0.46% price change this week, while RGNX (@Biotechnology) price change was -0.47% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.22%. For the same industry, the average monthly price growth was +31.37%, and the average quarterly price growth was +12.88%.

Reported Earning Dates

ASMB is expected to report earnings on May 08, 2025.

RGNX is expected to report earnings on Jul 30, 2025.

Industries' Descriptions

@Biotechnology (+4.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RGNX($423M) has a higher market cap than ASMB($132M). ASMB YTD gains are higher at: 9.696 vs. RGNX (8.538). ASMB has higher annual earnings (EBITDA): -44.5M vs. RGNX (-122.44M). RGNX has more cash in the bank: 268M vs. ASMB (91M). ASMB has less debt than RGNX: ASMB (3.02M) vs RGNX (79.8M). RGNX has higher revenues than ASMB: RGNX (157M) vs ASMB (32.2M).
ASMBRGNXASMB / RGNX
Capitalization132M423M31%
EBITDA-44.5M-122.44M36%
Gain YTD9.6968.538114%
P/E RatioN/AN/A-
Revenue32.2M157M21%
Total Cash91M268M34%
Total Debt3.02M79.8M4%
FUNDAMENTALS RATINGS
ASMB vs RGNX: Fundamental Ratings
ASMB
RGNX
OUTLOOK RATING
1..100
3156
VALUATION
overvalued / fair valued / undervalued
1..100
49
Fair valued
73
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9896
PRICE GROWTH RATING
1..100
3860
P/E GROWTH RATING
1..100
10021
SEASONALITY SCORE
1..100
508

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ASMB's Valuation (49) in the Pharmaceuticals Other industry is in the same range as RGNX (73) in the Biotechnology industry. This means that ASMB’s stock grew similarly to RGNX’s over the last 12 months.

ASMB's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as RGNX (100) in the Biotechnology industry. This means that ASMB’s stock grew similarly to RGNX’s over the last 12 months.

RGNX's SMR Rating (96) in the Biotechnology industry is in the same range as ASMB (98) in the Pharmaceuticals Other industry. This means that RGNX’s stock grew similarly to ASMB’s over the last 12 months.

ASMB's Price Growth Rating (38) in the Pharmaceuticals Other industry is in the same range as RGNX (60) in the Biotechnology industry. This means that ASMB’s stock grew similarly to RGNX’s over the last 12 months.

RGNX's P/E Growth Rating (21) in the Biotechnology industry is significantly better than the same rating for ASMB (100) in the Pharmaceuticals Other industry. This means that RGNX’s stock grew significantly faster than ASMB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ASMBRGNX
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
N/A
Stochastic
ODDS (%)
Bearish Trend 3 days ago
83%
Bullish Trend 3 days ago
83%
Momentum
ODDS (%)
Bullish Trend 7 days ago
80%
Bearish Trend 3 days ago
87%
MACD
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 3 days ago
88%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
85%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
79%
Bearish Trend 3 days ago
87%
Advances
ODDS (%)
Bullish Trend 5 days ago
78%
Bullish Trend 19 days ago
75%
Declines
ODDS (%)
N/A
Bearish Trend 7 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
N/A
Aroon
ODDS (%)
Bullish Trend 3 days ago
89%
Bullish Trend 3 days ago
61%
View a ticker or compare two or three
Interact to see
Advertisement
ASMB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RTIUX13.300.08
+0.61%
Russell Inv Tax-Managed Intl Eq M
GTDYX36.790.11
+0.30%
Invesco EQV Emerging Markets All Cap Y
ARIBX14.890.04
+0.27%
Aristotle Small Cap Eq I
SLPSX86.150.02
+0.02%
ProFunds Small Cap Svc
GLEPX13.90-0.04
-0.27%
GS Energy Infrastructure Fd Instl Shares